GMAB - Genmab A/S GAAP EPS of DKK83.65 revenue of DKK14.6B; initiates FY23 outlook
- Genmab A/S press release ( GMAB ): FY GAAP EPS of DKK83.65.
- Revenue of DKK14.6B (+72.2% Y/Y).
- Outlook: Genmab expects its 2023 revenue to be in the range of DKK 14,600–16,100 million, compared to DKK 14,595 million in 2022.
- Genmab’s projected revenue for 2023 primarily consists of DARZALEX royalties of DKK 10,400– 11,100 million. Such royalties are based on estimated DARZALEX 2023 net sales of USD 9.4–10.0 billion compared to actual net sales in 2022 of approximately USD 8.0 billion.
- Genmab anticipates its 2023 operating expenses to be in the range of DKK 9,800–10,600 million, compared to DKK 8,238 million in 2022.
- Genmab expects our operating profit to be in the range of DKK 3,900–6,200 million in 2023, compared to DKK 6,357 million in 2022.
For further details see:
Genmab A/S GAAP EPS of DKK83.65, revenue of DKK14.6B; initiates FY23 outlook